Zomedica Announces Publication of Case Series Highlighting Success with PulseVet(R) Shock Wave Therapy for Difficult to Treat Fibrotic Myopathy in Working Dogs
- None.
- None.
Insights
The recent findings on the use of PulseVet electro-hydraulic shock wave therapy to treat fibrotic myopathy in working dogs, such as German Shepherds, is a significant development in veterinary medicine. Fibrotic myopathy can severely limit the mobility and functionality of these dogs, which are critical in military and police operations. The ability to extend their working life not only has implications for the welfare of the animals but also represents a cost-saving measure for the organizations that depend on them. The treatment's impact on tissue regeneration and healing, through the stimulation of cells and release of growth factors, showcases an advancement in non-invasive therapies that could change standard care practices for similar conditions.
Zomedica's PulseVet technology's success in treating a previously challenging condition opens up new market opportunities for the company. As the therapy gains recognition for its efficacy, demand could increase from veterinary practices and institutions that manage working dogs. The expansion of the technology into new indications, such as osteoarthritis and potential pulmonary issues in equines and canines, suggests a strategic move to diversify and strengthen Zomedica's product portfolio. This could positively affect the company's financial health by tapping into the growing market for advanced veterinary treatments, which is fueled by increasing pet ownership and the humanization of pet care.
The publication of this case series article may have a favorable impact on Zomedica's stock performance. Investors often respond positively to advancements that can lead to increased market share and revenue growth. The clinical validation of PulseVet therapy across multiple indications represents a competitive edge in the veterinary healthcare market. Furthermore, the ongoing research into additional applications for the therapy could signal long-term growth potential for Zomedica. It is important, however, for investors to consider the costs associated with such research and development activities and how they might affect the company's financials in the short term, while keeping an eye on the long-term potential return on investment.
ANN ARBOR, MI / ACCESSWIRE / March 7, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the publication of a case series article supporting the use of PulseVet electro-hydraulic shock wave therapy to successfully treat canine patients with fibrotic myopathy. This condition primarily affects breeds associated with Military and Police working dogs, such as German Shepherd Dogs. In this series, the patients were able to continue working an average of 32 months following diagnosis.
The article, titled "Outcome of eight working dogs with fibrotic myopathy following extracorporeal shockwave and rehabilitation therapy: a case series" was recently published in Frontiers in Veterinary Science. The study was conducted by Drs. Frank Tsai, Leilani Alvarez and the team at the Department of Integrative and Rehabilitative Medicine, Schwarzman Animal Medical Center (New York, NY), and is available here: https://www.frontiersin.org/articles/10.3389/fvets.2023.1258319/full
PulseVet's electrohydraulic shock wave therapy has been clinically validated for multiple indications in canine and equine patients such as tendon and ligament healing, bone healing, alleviation of chronic back pain, osteoarthritis, and wound healing.
Dr. Leilani Alvarez, Department Head of Integrative and Rehabilitative Medicine Department at the Schwarzman Animal Medical Center, and a co-author of the article, stated, "fibrotic myopathy is a career ending condition for these highly trained working dogs and has historically been virtually impossible to successfully treat. Having the ability to offer a treatment option to significantly extend their working life is extremely gratifying."
PulseVet's shock wave therapy harnesses high-energy sound waves to stimulate cells and promote the release of healing growth factors within the body which have been shown to modulate inflammation, enhance blood flow, increase bone density, and accelerate healing.
Adrian Lock, Vice President of Veterinary and Clinical Affairs at Zomedica, stated, "PulseVet shock wave continues to set the standard for clinically proven efficacy in animal healthcare. Considering the time and dedication put into training military and police dogs, this particular condition can be utterly devastating. Using PulseVet shock wave to treat these extremely valuable animals we may be able to keep them working several years longer than they might have following this diagnosis."
"We are extremely proud of our PulseVet platform as it continues to outshine all other energy-based treatment modalities," added Larry Heaton, Zomedica's Chief Executive Officer. "Performing exceptionally well in this extremely challenging indication is another example of Zomedica and PulseVet expanding the boundaries of what can be achieved in animal health. Each new indication for this technology not only brings the benefit to new pet patients, but it also expands the market opportunity for Zomedica. With extensive research currently underway evaluating PulseVet therapy for osteoarthritis and early research in equine and canine pulmonary indications, we are very enthusiastic about the benefits we are bringing to veterinary patients globally."
Zomedica remains steadfast in its commitment to staying at the forefront of non-invasive, regenerative options in veterinary care. It's unwavering dedication to advancing veterinary care is demonstrated through its ongoing clinical studies, which have yielded promising results in various shock wave areas.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com.
Follow Zomedica
- Email Alerts: http://investors.zomedica.com
- LinkedIn: https://www.linkedin.com/company/zomedica
- Facebook: https://m.facebook.com/zomedica
- X (formerly Twitter): https://twitter.com/zomedica
- Instagram: https://www.instagram.com/zomedica_inc
Cautionary Statement Regarding Forward-Looking Statements - Safe Harbor
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products including acceptance for a particular indication; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.ca. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on accesswire.com
FAQ
What is the therapy used by Zomedica to treat fibrotic myopathy in working dogs?
Where was the case series article supporting the therapy published?
Who conducted the study on the use of PulseVet therapy for fibrotic myopathy?
What are some indications for which PulseVet therapy has been clinically validated?
Who is the Vice President of Veterinary and Clinical Affairs at Zomedica?
